Home » Topics » Regulatory » EMA

EMA
RSS

CHMP recommends conditional marketing approval for Votrient

April 27, 2010

CHMP recommends Seroquel XR as add-on treatment for major depressive disorder

April 27, 2010

EMA's CHMP recommends extending indication of tocilizumab

April 27, 2010

EMA's COMP notifies CytRX of positive opinion on bafetinib in CML

April 22, 2010

EMA recommends Cell Therapeutics submit revised PIP for pixantrone

April 22, 2010

European Joulferon MAA for chronic hepatitis C withdrawn

April 21, 2010

Aeterna Zentaris receives advice from the EMA for phase III perifosine program

April 16, 2010

Raloxifene decreases epistaxis in hereditary hemorrhagic telangiectasia / News in Context

April 13, 2010

EMA grants orphan drug designation to Protalix's taliglucerase alfa for Gaucher's disease

March 30, 2010

Bioalliance Pharma's antiemetic Setofilm approved in Europe

March 30, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.